Study of 5 million people of all backgrounds finds variations in hundreds of genes; previous studies were on people of ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

The largest and most diverse genetic study of depression has identified 300 new genetic risk factors for the condition across ...

Scientists said the British-led study provides more hope than ever before that the condition could be tackled through new ...

Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Narcolepsy. ORLANDO, FLORIDA / ACCESSWIRE / January 9, 2025 / The Assistance Fund, an indep ...

Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders.

Avadel said it expects Lumryz to generate about $50 million in revenue for the fourth quarter, missing current analyst forecasts by $3.7 million, and $169 million for the full year, $1.7 million shy ...